Cyclic nucleotide phosphodiesterases: Molecular regulation to clinical use

Pharmacological Reviews

Volumn 58, Issue 3, 2006, Pages 488-520

  Bender, Andrew T ^a   Beavo, Joseph A ^a,b  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 METHYL 5 NITROBENZENESULFONIC ACID DIMETHYLAMIDE; 3 (3 CYCLOPENTYLOXY 4 METHOXYBENZYL) 6 ETHYLAMINO 8 ISOPROPYL 3H PURINE; 4 (3 BUTOXY 4 METHOXYBENZYL) 2 IMIDAZOLIDINONE; BAY 60 7550; BAY 73 6691; CILOMILAST; CILOSTAMIDE; CILOSTAZOL; CYCLIC NUCLEOTIDE PHOSPHODIESTERASE; DIPYRIDAMOLE; IC 224; IC 242; IC 933; ISOBUTYLMETHYLXANTHINE; MILRINONE; N (3,5 DICHLORO 1 OXIDO 4 PYRIDINYL) 8 METHOXY 2 TRIFLUOROMETHYL 5 QUINOLINECARBOXAMIDE; N (3,5 DICHLORO 4 PYRIDYL) [1 (4 FLUOROBENZYL) 5 HYDROXY 3 INDOLYL]GLYOXYLIC ACID AMIDE; OPC 33540; PHOSPHODIESTERASE I; PHOSPHODIESTERASE III; PHOSPHODIESTERASE III INHIBITOR; PHOSPHODIESTERASE INHIBITOR; PHOSPHODIESTERASE IV INHIBITOR; PHOSPHODIESTERASE V; PHOSPHODIESTERASE V INHIBITOR; ROFLUMILAST; ROLIPRAM; SCH 5186; SILDENAFIL; SPLEEN EXONUCLEASE; TADALAFIL; TREQUINSIN; UDENAFIL; UNCLASSIFIED DRUG; UNINDEXED DRUG; VARDENAFIL; VINPOCETINE; ZAPRINAST; ZARDAVERINE;

ALZHEIMER DISEASE; CELL PROLIFERATION; CENTRAL NERVOUS SYSTEM DISEASE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CRYSTAL STRUCTURE; DRUG ACTIVITY; DRUG POTENCY; DRUG SELECTIVITY; DRUG TARGETING; ENZYME ACTIVITY; ENZYME ANALYSIS; ENZYME KINETICS; ENZYME LOCALIZATION; ENZYME PHOSPHORYLATION; ENZYME REGULATION; ENZYME SPECIFICITY; ENZYME STRUCTURE; ERECTILE DYSFUNCTION; HEART ARRHYTHMIA; HEART DISEASE; HEART FAILURE; HIGH THROUGHPUT SCREENING; HUMAN; INFLAMMATION; INTERMITTENT CLAUDICATION; LEARNING; LYMPHOCYTE; MEMORY; MENTAL DISEASE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN FAMILY; PROTEIN FUNCTION; PULMONARY HYPERTENSION; REVIEW; SMOOTH MUSCLE FIBER; SPERM; STROKE; THROMBOCYTE; VASCULAR SMOOTH MUSCLE; VISUAL DISORDER; VOMITING; X RAY CRYSTALLOGRAPHY;

ANIMALS; HUMANS; MODELS, BIOLOGICAL; MODELS, MOLECULAR; MULTIGENE FAMILY; NUCLEOTIDES, CYCLIC; PHOSPHODIESTERASE INHIBITORS; PHOSPHORIC DIESTER HYDROLASES;

EID: 33748686575     PISSN: 00316997     EISSN: 15210081     Source Type: Journal    
DOI: 10.1124/pr.58.3.5     Document Type: Review

References (270)

1. Abrahamsen H, Baillie G, Ngai J, Vang T, Nika K, Ruppelt A, Mustelin T, Zaccolo M, Houslay M, and Tasken K (2004) TCR- and CD28-mediated recruitment of phosphodiesterase 4 to lipid rafts potentiates TCR signaling. J Immunol 173:4847-4858.
2. Adams SR, Harootunian AT, Buechler YJ, Taylor SS, and Tsien RY (1991) Fluorescence ratio imaging of cyclic AMP in single cells. Nature (Lond) 349:694-697.
3. Andreeva SG, Dikkes P, Epstein PM, and Rosenberg PA (2001) Expression of cGMP-specific phosphodiesterase 9A mRNA in the rat brain. J Neurosci 21:9068-9076.
4. Ang KL and Antoni FA (2002) Reciprocal regulation of calcium dependent and calcium independent cyclic AMP hydrolysis by protein phosphorylation. J Neurochem 81:422-433.
5. Ariga M, Neitzert B, Nakae S, Mottin G, Bertrand C, Pruniaux MP, Jin SL, and Conti M (2004) Nonredundant function of phosphodiesterases 4D and 4B in neutrophil recruitment to the site of inflammation. J Immunol 173:7531-7538.
6. Asirvatham AL, Galligan SG, Schillace RV, Davey MP, Vasta V, Beavo JA, and Carr DW (2004) A-kinase anchoring proteins interact with phosphodiesterases in T lymphocyte cell lines. J Immunol 173:4806-4814.
7. Barnette MS, Christensen SB, Essayan DM, Grous M, Prabhakar U, Rush JA, Kagey-Sobotka A, and Torphy TJ (1998) SB 207499 (Ariflo), a potent and selective second-generation phosphodiesterase 4 inhibitor: in vitro anti-inflammatory actions. J Pharmacol Exp Ther 284:420-426.
8. Beard MB, O'Connell JC, Bolger GB, and Houslay MD (1999) The unique N-terminal domain of the cAMP phosphodiesterase PDE4D4 allows for interaction with specific SH3 domains. FEBS Lett 460:173-177.
9. Beavo JA, Conti M, and Heaslip RJ (1994) Multiple cyclic nucleotide phosphodiesterases. Mol Pharmacol 46:399-405.
10. Beavo JA, Hansen RS, Harrison SA, Hurwitz RL, Martins TJ, and Mumby MC (1982) Identification and properties of cyclic nucleotide phosphodiesterases. Mol Cell Endocrinol 28:387-410.
11. Bender AT, Ostenson CL, Giordano D, and Beavo JA (2004) Differentiation of human monocytes in vitro with granulocyte-macrophage colony-stimulating factor and macrophage colony-stimulating factor produces distinct changes in cGMP phophodiesterase expression. Cell Signal 16:365-374.
12. Bender AT, Ostenson CL, Wang EH, and Beavo JA (2005) Selective up-regulation of PDE1B2 upon monocyte-to-macrophage differentiation. Proc Natl Acad Sci USA 102:497-502.
13. Billah M, Cooper N, Cuss F, Davenport RJ, Dyke HJ, Egan R, Ganguly A, Gowers L, Hannah DR, Haughan AF, et al. (2002) Synthesis and profile of SCH351591, a novel PDE4 inhibitor. Bioorg Med Chem Lett 12:1621-1623.
14. Bischoff E (2004) Potency, selectivity, and consequences of nonselectivity of PDE inhibition. Int J Impot Res 16 (Suppl 1):S11-S14.
15. Bischoff E, Niewoehner U, Haning H, Es Sayed M, Schenke T, and Schlemmer KH (2001) The oral efficacy of vardenafil hydrochloride for inducing penile erection in a conscious rabbit model. J Urol 165:1316-1318.
16. Bloom TJ and Beavo JA (1996) Identification and tissue-specific expression of PDE7 phosphodiesterase splice variants. Proc Natl Acad Sci USA 93:14188-14192.
17. Boess FG, Hendrix M, van der Staay FJ, Erb C, Schreiber R, van Staveren W, de Vente J, Prickaerts J, Blokland A, and Koenig G (2004) Inhibition of phosphodiesterase 2 increases neuronal cGMP, synaptic plasticity and memory performance. Neuropharmacology 47:1081-1092.
18. Boolell M, Allen MJ, Ballard SA, Gepi-Attee S, Muirhead GJ, Naylor AM, Osterloh IH, and Gingell C (1996) Sildenafil: an orally active type 5 cyclic GMP-specific phosphodiesterase inhibitor for the treatment of penile erectile dysfunction. Int J Impot Res 8:47-52.
19. Butcher RW and Sutherland EW (1962) Adenosine 3′,5′-phosphate in biological materials. J Biol Chem 237:1244-1250.
20. Card GL, Blasdel L, England BP, Zhang C, Suzuki Y, Gillette S, Fong D, Ibrahim PN, Artis DR, Bollag G, et al. (2005) A family of phosphodiesterase inhibitors discovered by cocrystallography and scaffold-based drug design. Nat Biotechnol 23:201-207.
21. Card GL, England BP, Suzuki Y, Fong D, Powell B, Lee B, Luu C, Tabrizizad M, Gillette S, Ibrahim PN, et al. (2004) Structural basis for the activity of drugs that inhibit phosphodiesterases. Structure 12:2233-2247.
22. Castro A, Jerez MJ, Gil C, and Martinez A (2005) Cyclic nucleotide phosphodiesterases and their role in immunomodulatory responses: advances in the development of specific phosphodiesterase inhibitors. Med Res Rev 25:229-244.
23. Cheung WY (1970) Cyclic nucleotide 3′,5′-nucleotide phosphodiesterase: evidence for and properties of a protein activator. Biochem Biophys Res Commun 38:533-538.
24. Choi YH, Ekholm D, Krall J, Ahmad F, Degerman E, Manganiello VC, and Movsesian MA (2001) Identification of a novel isoform of the cyclic-nucleotide phosphodiesterase PDE3A expressed in vascular smooth-muscle myocytes. Biochem J 353 (Pt 1):41-50.
25. Conti M, Andersen CB, Richard F, Mehats C, Chun SY, Horner K, Jin C, and Tsafriri A (2002) Role of cyclic nucleotide signaling in oocyte maturation. Mol Cell Endocrinol 187:153-159.
26. Cook TA, Ghomashchi F, Gelb MH, Florio SK, and Beavo JA (2000) Binding of the δ subunit to rod phosphodiesterase catalytic subunits requires methylated, prenylated C-termini of the catalytic subunits. Biochemistry 39:13516-13523.
27. Cook TA, Ghomashchi F, Gelb MH, Florio SK, and Beavo JA (2001) The δ subunit of type 6 phosphodiesterase reduces light-induced cGMP hydrolysis in rod outer segments. J Biol Chem 276:5248-5255.
28. Coquil JF, Franks DJ, Wells JN, Dupuis M, and Hamet P (1980) Characteristics of a new binding protein distinct from the kinase for guanosine 3′:5′-monophosphate in rat platelets. Biochim Biophys Acta 631:148-165.
29. Corbin JD (2004) Mechanisms of action of PDE5 inhibition in erectile dysfunction. Int J Impot Res 16 (Suppl 1):S4-S7.
30. Corbin JD, Turko IV, Beasley A, and Francis SH (2000) Phosphorylation of phosphodiesterase-5 by cyclic nucleotide-dependent protein kinase alters its catalytic and allosteric cGMP-binding activities. Eur J Biochem 267:2760-2767.
31. Cote RH (2004) Characteristics of photoreceptor PDE (PDE6): similarities and differences to PDE5. Int J Impot Res 16 (Suppl 1):S28-S33.
32. D'Andrea MR, Qiu Y, Haynes-Johnson D, Bhattacharjee S, Kraft P, and Lundeen S (2005) Expression of PDE11A in normal and malignant human tissues. J Histochem Cytochem 53:895-903.
33. Das A, Xi L, and Kukreja RC (2005) Phosphodiesterase-5 inhibitor sildenafil preconditions adult cardiac myocytes against necrosis and apoptosis: essential role of nitric oxide signaling. J Biol Chem 280:12944-12955.
34. Das S, Maulik N, Das DK, Kadowitz PJ, and Bivalacqua TJ (2002) Cardioprotection with sildenafil, a selective inhibitor of cyclic 3′,5′-monophosphate-specific phosphodiesterase 5. Drugs Exp Clin Res 28:213-219.
35. Davis RL, Takayasu H, Eberwine M, and Myres J (1989) Cloning and characterization of mammalian homologs of the Drosophila dunce+ gene. Proc Natl Acad Sci USA 86:3604-3608.
36. Day JP, Dow JA, Houslay MD, and Davies SA (2005) Cyclic nucleotide phosphodiesterases in Drosophila melanogaster. Biochem J 388 (Pt 1):333-342.
37. Day JP, Houslay MD, and Davies SA (2006) A novel role for a Drosophila homologue of cGMP-specific phosphodiesterase in the active transport of cGMP. Biochem J 393 (Pt 2):481-488.
38. Degerman E, Belfrage P, Newman AH, Rice KC, and Manganiello VC (1987) Purification of the putative hormone-sensitive cyclic AMP phosphodiesterase from rat adipose tissue using a derivative of cilostamide as a novel affinity ligand. J Biol Chem 262:5797-5807.
39. Dickinson NT, Jang EK, and Haslam RJ (1997) Activation of cGMP-stimulated phosphodiesterase by nitroprusside limits cAMP accumulation in human platelets: effects on platelet aggregation. Biochem J 323:371-377.
40. Ding B, Abe J, Wei H, Huang Q, Walsh RA, Molina CA, Zhao A, Sadoshima J, Blaxall BC, Berk BC, et al. (2005) Functional role of phosphodiesterase 3 in cardiomyocyte apoptosis: implication in heart failure. Circulation 111:2469-2476.
41. Dodge KL, Khouangsathiene S, Kapiloff MS, Mouton R, Hill EV, Houslay MD, Langeberg LK, and Scott JD (2001) mAKAP assembles a protein kinase A/PDE4 phosphodiesterase cAMP signaling module. EMBO (Eur Mol Biol Organ) J 20:1921-1930.
42. Dunkerley HA, Tilley DG, Palmer D, Liu H, Jimmo SL, and Maurice DH (2002) Reduced phosphodiesterase 3 activity and phosphodiesterase 3A level in synthetic vascular smooth muscle cells: implications for use of phosphodiesterase 3 inhibitors in cardiovascular tissues. Mol Pharmacol 61:1033-1040.
43. Dunkern TR and Hatzelmann A (2005) The effect of sildenafil on human platelet secretory function is controlled by a complex interplay between phosphodiesterases 2, 3 and 5. Cell Signal 17:331-339.
44. Dunlap JC, Loros JJ, Liu Y, and Crosthwaite SK (1999) Eukaryotic circadian systems: cycles in common. Genes Cells 4:1-10.
45. Ekholm D, Belfrage P, Manganiello V, and Degerman E (1997) Protein kinase A-dependent activation of PDE4 (cAMP-specific cyclic nucleotide phosphodiesterase) in cultured bovine vascular smooth muscle cells. Biochim Biophys Acta 1356:64-70.
46. Essayan DM (2001) Cyclic nucleotide phosphodiesterases. J Allergy Clin Immunol Nov 108:671-680.
47. Evellin S, Mongillo M, Terrin A, Lissandron V, and Zaccolo M (2004) Measuring dynamic changes in cAMP using fluorescence resonance energy transfer. Methods Mol Biol 284:259-270.
48. Farber DB and Tsang SH (2003) Stationary night blindness or progressive retinal degeneration in mice carrying different alleles of PDE γ. Front Biosci 8:s666-s675.
49. Fawcett L, Baxendale R, Stacey P, McGrouther C, Harrow I, Soderling S, Hetman J, Beavo JA, and Phillips SC (2000) Molecular cloning and characterization of a distinct human phosphodiesterase gene family: PDE11A. Proc Natl Acad Sci USA 97:3702-3707.
50. Fischmeister R, Castro L, Abi-Gerges A, Rochais F, and Vandecasteele G (2005) Species- and tissue-dependent effects of NO and cyclic GMP on cardiac ion channels. Comp Biochem Physiol A 142:136-143.
51. Fisher DA, Smith JF, Pillar JS, St Denis SH, and Cheng JB (1998a) Isolation and characterization of PDE8A, a novel human cAMP-specific phosphodiesterase. Biochem Biophys Res Commun 246:570-577.
52. Fisher DA, Smith JF, Pillar JS, St Denis SH, and Cheng JB (1998b) Isolation and characterization of PDE9A, a novel human cGMP-specific phosphodiesterase. J Biol Chem 273:15559-15564.
53. Francis SH, Bessay EP, Kotera J, Grimes KA, Liu L, Thompson WJ, and Corbin JD (2002) Phosphorylation of isolated human phosphodiesterase-5 regulatory domain induces an apparent conformational change and increases cGMP binding affinity. J Biol Chem 277:47581-47587.
54. Francis SH, Blount MA, Zoraghi R, and Corbin JD (2005) Molecular properties of mammalian proteins that interact with cGMP: protein kinases, cation channels, phosphodiesterases, and multi-drug anion transporters. Front Biosci 10:2097-2117.
55. Francis SH, Lincoln TM, and Corbin JD (1980) Characterization of a novel cGMP binding protein from rat lung. J Biol Chem 255:620-626.
56. Fujishige K, Kotera J, Michibata H, Yuasa K, Takebayashi S, Okumura K, and Omori K (1999a) Cloning and characterization of a novel human phosphodiesterase that hydrolyzes both cAMP and cGMP (PDE10A). J Biol Chem 274:18438-18445.
57. Fujishige K, Kotera J, and Omori K (1999b) Striatum- and testis-specific phosphodiesterase PDE10A isolation and characterization of a rat PDE10A. Eur J Biochem 266:1118-1127.
58. Gal A, Orth U, Baehr W, Schwinger E, and Rosenberg T (1994) Heterozygous missense mutation in the rod cGMP phosphodiesterase β-subunit gene in autosomal dominant stationary night blindness. Nat Genet 7:64-68.
59. Gale DD, Landells LJ, Spina D, Miller AJ, Smith K, Nichols T, Rotshteyn Y, Tonelli A, Lacouture P, Burch RM, et al. (2002) Pharmacokinetic and pharmacodynamic profile following oral administration of the phosphodiesterase (PDE)4 inhibitor V11294A in healthy volunteers. Br J Clin Pharmacol 54:478-484.
60. Galperin MY, Nikolskaya AN, and Koonin EV (2001) Novel domains of the prokaryotic two-component signal transduction systems. FEMS Microbiol Lett 203:11-21.
61. Gamanuma M, Yuasa K, Sasaki T, Sakurai N, Kotera J, and Omori K (2003) Comparison of enzymatic characterization and gene organization of cyclic nucleotide phosphodiesterase 8 family in humans. Cell Signal 15:565-574.
62. Gardner C, Robas N, Cawkill D, and Fidock M (2000) Cloning and characterization of the human and mouse PDE7B, a novel cAMP-specific cyclic nucleotide phosphodiesterase. Biochem Biophys Res Commun 272:186-192.
63. Gilles-Gonzalez MA and Gonzalez G (2004) Signal transduction by heme-containing PAS-domain proteins. J Appl Physiol 96:774-783.
64. Gillespie PG and Beavo JA (1988) Characterization of a bovine cone photoreceptor phosphodiesterase purified by cyclic GMP-Sepharose chromatography. J Biol Chem 263:8133-8141.
65. Giordano D, De Stefano ME, Citro G, Modica A, and Giorgi M (2001) Expression of cGMP-binding cGMP-specific phosphodiesterase (PDE5) in mouse tissues and cell lines using an antibody against the enzyme amino-terminal domain. Biochim Biophys Acta 1539:16-27.
66. Glavas NA, Ostenson C, Schaefer JB, Vasta V, and Beavo JA (2001) T cell activation up-regulates cyclic nucleotide phosphodiesterases 8A1 and 7A3. Proc Natl Acad Sci USA 98:6319-6324.
67. 18O incorporation into nucleotide alpha-phosphoryls corresponds with intensity of photic stimulation. J Biol Chem 258:9213-9219.
68. 2+-calmodulin-dependent phosphodiesterase (PDE1): current perspectives. Cell Signal 17:789-797.
69. Granovsky AE, Natochin M, McEntaffer RL, Haik TL, Francis SH, Corbin JD, and Artemyev NO (1998) Probing domain functions of chimeric PDE6α′/ PDE5 cGMP-phosphodiesterase. J Biol Chem 273:24485-24490.
70. Grant PG and Colman RW (1984) Purification and characterization of a human platelet cyclic nucleotide phosphodiesterase. Biochemistry 23:1801-1807.
71. Gretarsdottir S, Thorleifsson G, Reynisdottir ST, Manolescu A, Jonsdottir S, Jonsdottir T, Gudmundsdottir T, Bjarnadottir SM, Einarsson OB, Gudjonsdottir HM, et al. (2003) The gene encoding phosphodiesterase 4D confers risk of ischemic stroke. Nat Genet 35:131-138.
72. Gross-Langenhoff M, Hofbauer K, Weber J, Schultz A, and Schultz JE (2006) cAMP is a ligand for the tandem GAF domain of human phosphodiesterase 10 and cGMP for the tandem GAF domain of phosphodiesterase 11. J Biol Chem 281:2841-2846.
73. Guipponi M, Scott HS, Kudoh J, Kawasaki K, Shibuya K, Shintani A, Asakawa S, Chen H, Lalioti MD, Rossier C, et al. (1998) Identification and characterization of a novel cyclic nucleotide phosphodiesterase gene (PDE9A) that maps to 21q22.3: alternative splicing of mRNA transcripts, genomic structure and sequence. Hum Genet 103:386-392.
74. Hagiwara M, Endo T, and Hidaka H (1984) Effects of vinpocetine on cyclic nucleotide metabolism in vascular smooth muscle. Biochem Pharmacol 33(3):453-457.
75. Hamet P and Coquil JF (1978) Cyclic GMP binding and cyclic GMP phosphodiesterase in rat platelets. J Cyclic Nucleotide Res 4:281-290.
76. Han P, Zhu XY, and Michaeli T (1997) Alternative splicing of the high affinity cAMP-specific phosphodiesterase (PDE7A) mRNA in human skeletal muscle and heart. J Biol Chem 272:16152-16157.
77. Hansen RS, Charbonneau H, and Beavo JA (1988) Purification of calmodulin-stimulated cyclic nucleotide phosphodiesterase by monoclonal antibody affinity chromatography. Methods Enzymol 159:543-557.
78. Harrison SA, Reifsnyder DH, Gallis B, Cadd GG, and Beavo JA (1986) Isolation and characterization of bovine cardiac muscle cGMP-inhibited phosphodiesterase: a receptor for new cardiotonic drugs. Mol Pharmacol 29:506-514.
79. 2+/calmodulin-dependent protein kinase II. J Biol Chem 264:10884-10887.
80. Hassan MA and Ketat AF (2005) Sildenafil citrate increases myocardial cGMP content in rat heart, decreases its hypertrophic response to isoproterenol and decreases myocardial leak of creatine kinase and troponin T. BMC Pharmacol 5:10.
81. Hatzelmann A and Schudt C (2001) Anti-inflammatory and immunomodulatory potential of the novel PDE4 inhibitor roflumilast in vitro. J Pharmacol Exp Ther 297:267-279.
82. Hayashi M, Shimada Y, Nishimura Y, Hama T, and Tanaka T (2002) Genomic organization, chromosomal localization, and alternative splicing of the human phosphodiesterase 8B gene. Biochem Biophys Res Commun 297:1253-1258.
83. Hebb AL, Robertson HA, and Denovan-Wright EM (2004) Striatal phosphodiesterase mRNA and protein levels are reduced in Huntington's disease transgenic mice prior to the onset of motor symptoms. Neuroscience 123:967-981.
84. Hendrix M (2005) Selective Inhibitors of cGMP phosphodiesterases as precognitive agents. BMC Pharmacol S5:64.
85. Hetman JM, Robas N, Baxendale R, Fidock M, Phillips SC, Soderling SH, and Beavo, JA (2000a) Cloning and characterization of two splice variants of human phosphodiesterase 11A. Proc Natl Acad Sci USA 97:12891-12895.
86. Hetman JM, Soderling SH, Glavas NA, and Beavo JA (2000b) Cloning and characterization of PDE7B, a cAMP-specific phosphodiesterase. Proc Natl Acad Sci USA 97:472-476.
87. Hidaka H, Hayashi H, Kohri H, Kimura Y, Hosokawa T, Igawa T, and Saitoh Y (1979) Selective inhibitor of platelet cyclic adenosine monophosphate phosphodiesterase, cilostamide, inhibits platelet aggregation. J Pharmacol Exp Ther 211:26-30.
88. Hoeflich KP and Ikura M (2002) Calmodulin in action: diversity in target recognition and activation mechanisms. Cell 108:739-742.
89. Hoeper MM (2005) Drug treatment of pulmonary arterial hypertension: current and future agents. Drugs 65:1337-1354.
90. Houslay MD (2005) The long and short of vascular smooth muscle phosphodiesterase-4 as a putative therapeutic target. Mol Pharmacol 68:563-567.
91. Houslay MD and Adams DR (2003) PDE4 cAMP phosphodiesterases: modular enzymes that orchestrate signalling cross-talk, desensitization and compartmentalization. Biochem J 370 (Pt 1):1-18.
92. Hu H, McCaw EA, Hebb AL, Gomez GT, and Denovan-Wright EM (2004) Mutant huntingtin affects the rate of transcription of striatum-specific isoforms of phosphodiesterase 10A. Eur J Neurosci 20:3351-3363.
93. Huai Q, Colicelli J, and Ke H (2003a) The crystal structure of AMP-bound PDE4 suggests a mechanism for phosphodiesterase catalysis. Biochemistry 42:13220-13226.
94. Huai Q, Liu Y, Francis SH, Corbin JD, and Ke H (2004a) Crystal structures of phosphodiesterases 4 and 5 in complex with inhibitor 3-isobutyl-1- methylxanthine suggest a conformation determinant of inhibitor selectivity. J Biol Chem 279:13095-14101.
95. Huai Q, Wang H, Sun Y, Kim HY, Liu Y, and Ke H (2003b) Three-dimensional structures of PDE4D in complex with roliprams and implication on inhibitor selectivity. Structure 11:865-873.
96. Huai Q, Wang H, Zhang W, Colman RW, Robinson H, and Ke H (2004b) Crystal structure of phosphodiesterase 9 shows orientation variation of inhibitor 3-isobutyl-1-methylxanthine binding. Proc Natl Acad Sci USA 101:9624-9629.
97. Huang D, Hinds TR, Martinez SE, Doneanu C, and Beavo JA (2004) Molecular determinants of cGMP binding to chicken cone photoreceptor phosphodiesterase. J Biol Chem 279:48143-48151.
98. Humpl T, Reyes JT, Holtby H, Stephens D, and Adatia I (2005) Beneficial effect of oral sildenafil therapy on childhood pulmonary arterial hypertension: twelve-month clinical trial of a single-drug, open-label, pilot study. Circulation 111:3274-3280.
99. Huston E, Lumb S, Russell A, Catterall C, Ross AH, Steele MR, Bolger GB, Perry MJ, Owens RJ, and Houslay MD (1997) Molecular cloning and transient expression in COS7 cells of a novel human PDE4B cAMP-specific phosphodiesterase, HSPDE4B3. Biochem J 328 (Pt 2):549-558.
100. Ito M, Nishikawa M, Fujioka M, Miyahara M, Isaka N, Shiku H, and Nakano T (1996) Characterization of the isoenzymes of cyclic nucleotide phosphodiesterase in human platelets and the effects of E4021. Cell Signal 8:575-581.
101. Jeon YH, Heo YS, Kim CM, Hyun YL, Lee TG, Ro S, and Cho JM (2005) Phosphodiesterase: overview of protein structures, potential therapeutic applications and recent progress in drug development. Cell Mol Life Sci 62:1198-1220.
102. Jin SLC and Conti M (2002) Induction of the cyclic nucleotide phosphodiesterase PDE4B is essential for LPS-activated TNF-α responses. Proc Natl Acad Sci USA 99:7628-7633.
103. Jin SL, Lan L, Zoudilova M, and Conti M (2005a) Specific role of phosphodiesterase 4B in lipopolysaccharide-induced signaling in mouse macrophages. J Immunol 175:1523-1531.
104. Jin SL, Latour AM, and Conti M (2005b) Generation of PDE4 knockout mice by gene targeting. Methods Mol Biol 307:191-210.
105. Jin SL, Richard FJ, Kuo WP, D'Ercole AJ, and Conti M (1999) Impaired growth and fertility of cAMP-specific phosphodiesterase PDE4D-deficient mice. Proc Natl Acad Sci USA 96:11998-122003.
106. Juilfs DM, Fulle HJ, Zhao AZ, Houslay MD, Garbers DL, and Beavo JA (1997) A subset of olfactory neurons that selectively express cGMP-stimulated phosphodiesterase (PDE2) and guanylyl cyclase-D define a unique olfactory signal transduction pathway. Proc Natl Acad Sci USA 94:3388-3395.
107. Juilfs DM, Soderling S, Burns F, and Beavo JA (1999) Cyclic GMP as substrate and regulator of cyclic nucleotide phosphodiesterases (PDEs). Rev Physiol Biochem Pharmacol 135:67-104.
108. Kajimura N, Yamazaki M, Morikawa K, Yamazaki A, and Mayanagi K (2002) Three-dimensional structure of non-activated cGMP phosphodiesterase 6 and comparison of its image with those of activated forms. J Struct Biol 139:27-38.
109. Kakkar R, Raju RV, and Sharma RK (1999) Calmodulin-dependent cyclic nucleotide phosphodiesterase (PDE1). Cell Mol Life Sci 55: 1164-1186.
110. Kanacher T, Schultz A, Linder JU, and Schultz JE (2002) A GAF-domain-regulated adenylyl cyclase from Anabaena is a self- activating cAMP switch. EMBO (Eur Mol Biol Organ) J 21:3672-3680.
111. Ke H (2004) Implications of PDE4 structure on inhibitor selectivity across PDE families. Int J Impot Res 16 (Suppl 1):S24-S27.
112. Kenan Y, Murata T, Shakur Y, Degerman E, and Manganiello VC (2000) Functions of the N-terminal region of cyclic nucleotide phosphodiesterase 3 (PDE 3) isoforms. J Biol Chem 275:12331-12338.
113. Kim D, Rybalkin SD, Pi X, Wang Y, Zhang C, Munzel T, Beavo JA, Berk BC, and Yan C (2001) Upregulation of phosphodiesterase 1A1 expression is associated with the development of nitrate tolerance. Circulation 104:2338-2343.
114. Kincaid RL, Stith-Coleman IE, and Vaughan M (1985) Proteolytic activation of calmodulin-dependent cyclic nucleotide phosphodiesterase. J Biol Chem 260:9009-9015.
115. Kinoshita T, Kobayashi S, Ebara S, Yoshimura Y, Horiuchi H, Tsutsumimoto T, Wakabayashi S, and Takaoka K (2000) Phosphodiesterase inhibitors, pentoxifylline and rolipram, increase bone mass mainly by promoting bone formation in normal mice. Bone 27:811-817.
116. Kotera J, Fujishige K, Imai Y, Kawai E, Michibata H, Akatsuka H, Yanaka N, and Omori K (1999a) Genomic origin and transcriptional regulation of two variants of cGMP-binding cGMP-specific phosphodiesterases. Eur J Biochem 262:866-873.
117. Kotera J, Fujishige K, and Omori K (2000) Immunohistochemical localization of cGMP-binding cGMP-specific phosphodiesterase (PDE5) in rat tissues. J Histochem Cytochem 48:685-693.
118. Kotera J, Fujishige K, Yuasa K, and Omori K (1999b) Characterization and phosphorylation of PDE10A2, a novel alternative splice variant of human phosphodiesterase that hydrolyzes cAMP and cGMP. Biochem Biophys Res Commun 261:551-557.
119. Kraulis PJ (1991) MOLSCRIPT: a program to produce both detailed and schematic plots of protein structures. J Appl Crystallogr 24 (Pt 5):946-950.
120. Lee ME, Markowitz J, Lee JO, and Lee H (2000) Crystal structure of phosphodiesterase 4D and inhibitor complex. FEBS Lett 530: 53-58.
121. Lee R, Wolda S, Moon E, Esselstyn J, Hertel C, and Lerner A (2002) PDE7A is expressed in human B-lymphocytes and is up-regulated by elevation of intracellular cAMP. Cell Signal 14:277-284.
122. Lehnart SE, Wehrens XH, Reiken S, Warrier S, Belevych AE, Harvey RD, Richter W, Jin SL, Conti M, and Marks AR (2005) Phosphodiesterase 4D deficiency in the ryanodine-receptor complex promotes heart failure and arrhythmias. Cell 123:25-35.
123. Lewis GD and Semigran MJ (2004) Type 5 phosphodiesterase inhibition in heart failure and pulmonary hypertension. Curr Heart Fail Rep 1:183-189.
124. Li L, Yee C, and Beavo JA (1999) CD3- and CD28-dependent induction of PDE7 required for T cell activation. Science (Wash DC) 283:848-851.
125. Lin CS, Chow S, Lau A, Tu R, and Lue TF (2001a) Identification and regulation of human PDE5A gene promoter. Biochem Biophys Res Commun 280:684-692.
126. Lin CS, Chow S, Lau A, Tu R, and Lue TF (2001b) Regulation of human PDE5A2 intronic promoter by cAMP and cGMP: identification of a critical Sp1-binding site. Biochem Biophys Res Commun 280:693-699.
127. Lin CS, Chow S, Lau A, Tu R, and Lue TF (2002) Human PDE5A gene encodes three PDE5 isoforms from two alternate promoters. Int J Impot Res 14:15-24.
128. Lin CS, Lau A, Tu R, and Lue TF (2000) Expression of three isoforms of cGMP-binding cGMP-specific phosphodiesterase (PDE5) in human penile cavernosum. Biochem Biophys Res Commun 268:628-635.
129. Lipworth BJ (2005) Phosphodiesterase-4 inhibitors for asthma and chronic obstructive pulmonary disease. Lancet 365:167-175.
130. Loughney K, Hill TR, Florio VA, Uher L, Rosman GJ, Wolda SL, Jones BA, Howard ML, McAllister-Lucas LM, Sonnenburg WK, et al. (1998) Isolation and characterization of cDNAs encoding PDE5A, a human cGMP-binding, cGMP-specific 3′,5′-cyclic nucleotide phosphodiesterase. Gene 216:139-147.
131. Loughney K, Martins TJ, Harris EA, Sadhu K, Hicks JB, Sonnenburg WK, Beavo JA, and Ferguson K (1996) Isolation and characterization of cDNAs corresponding to two human calcium, calmodulin-regulated, 3′,5′- cyclic nucleotide phosphodiesterases. J Biol Chem 271:796-806.
132. Loughney K, Snyder PB, Uher L, Rosman GJ, Ferguson K, and Florio VA (1999) Isolation and characterization of PDE10A, a novel human 3′,5′-cyclic nucleotide phosphodiesterase. Gene 234:109-117.
133. Loughney K, Taylor J, and Florio VA (2005) 3′,5′-Cyclic nucleotide phosphodiesterase 11A: localization in human tissues. Int J Impot Res 17:320-325.
134. Lugnier C (2005) Cyclic nucleotide phosphodiesterase (PDE) superfamily: A new target for the development of specific therapeutic agents. Pharmacol Ther 109:366-398.
135. Lugnier C, Schoeffter P, Le BA, Strouthou E, and Stoclet JC (1986) Selective inhibition of cyclic nucleotide phosphodiesterases of human, bovine and rat aorta. Biochem Pharmacol 35:1743-1751.
136. MacFarland RT, Zelus BD, and Beavo JA (1991) High concentrations of a cGMP-stimulated phosphodiesterase mediate ANP-induced decreases in cAMP and steroidogenesis in adrenal glomerulosa cells. J Biol Chem 266:136-142.
137. Martinez SE, Bruder S, Schultz A, Zheng N, Schultz JE, Beavo JA, and Linder JU (2005) Crystal structure of the tandem GAF domains from a cyanobacterial adenylyl cyclase: modes of ligand binding and dimerization. Proc Natl Acad Sci USA 102:3082-3087.
138. Martinez SE, Wu A, Glavas N, Tang X, Turley S, Hol W, and Beavo J (2002) The two GAF domains in phosphodiesterase 2A have distinct roles in dimerization and in cGMP binding. Proc Nat Acad Sci USA 99:13260-13265.
139. Martins TJ, Mumby MC, and Beavo JA (1982) Purification and characterization of a cyclic GMP-stimulated cyclic nucleotide phosphodiesterase from bovine tissues. J Biol Chem 257:1973-1979.
140. Masciarelli S, Horner K, Liu C, Park SH, Hinckley M, Hockman S, Nedachi T, Jin C, Conti M, and Manganiello V (2004) Cyclic nucleotide phosphodiesterase 3A-deficient mice as a model of female infertility. J Clin Investig 114:196-205.
141. Maurice DH and Haslam RJ (1990) Molecular basis of the synergistic inhibition of platelet function by nitrovasodilators and activators of adenylate cyclase: inhibition of cyclic AMP breakdown by cyclic GMP. Mol Pharmacol 37:671-681.
142. Maurice DH, Palmer D, Tilley DG, Dunkerley HA, Netherton SJ, Raymond DR, Elbatarny HS, and Jimmo SL (2003) Cyclic nucleotide phosphodiesterase activity, expression, and targeting in cells of the cardiovascular system. Mol Pharmacol 64:533-546.
143. McAllister LLM, Sonnenburg WK, Kadlecek A, Seger D, Trong HL, Colbran JL, Thomas MK, Walsh KA, Francis SH, Corbin JD, et al. (1993) The structure of a bovine lung cGMP-binding, cGMP-specific phosphodiesterase deduced from a cDNA clone. J Biol Chem 268:22863-22873.
144. McLaughlin ME, Sandberg MA, Berson EL, and Dryja TP (1993) Recessive mutations in the gene encoding the β-subunit of rod phosphodiesterase in patients with retinitis pigmentosa. Nat Genet 4:130-134.
145. McPhee I, Yarwood SJ, Scotland G, Huston E, Beard MB, Ross AH, Houslay ES, and Houslay MD (1999) Association with the SRC family tyrosyl kinase LYN triggers a conformational change in the catalytic region of human cAMP-specific phosphodiesterase HSPDE4A4B: consequences for rolipram inhibition. J Biol Chem 274:11796-11810.
146. Mehats C, Jin SL, Wahlstrom J, Law E, Umetsu DT, and Conti M (2003) PDE4D plays a critical role in the control of airway smooth muscle contraction. FASEB J 17:1831-1841.
147. Mery PF, Pavoine C, Pecker F, and Fischmeister R (1995) Erythro-9-(2-hydroxy-3-nonyl)adenine inhibits cyclic GMP-stimulated phosphodiesterase in isolated cardiac myocytes. Mol Pharmacol 48:121-130.
148. Meyer MR, Angele A, Kremmer E, Kaupp UB, and Muller F (2000) A cGMP-signaling pathway in a subset of olfactory sensory neurons. Proc Natl Acad Sci USA 97:10595-10600.
149. Michaeli T, Bloom TJ, Martins T, Loughney K, Ferguson K, Riggs M, Rodgers L, Beavo JA, and Wigler M (1993) Isolation and characterization of a previously undetected human cAMP phosphodiesterase by complementation of cAMP phosphodiesterase-deficient Saccharomyces cerevisiae. J Biol Chem 268:12925-12932.
150. Millar JK, Pickard BS, Mackie S, James R, Christie S, Buchanan SR, Malloy MP, Chubb JE, Huston E, Baillie GS, et al. (2005) DISC1 and PDE4B are interacting genetic factors in schizophrenia that regulate cAMP signaling. Science (Wash DC) 310:1187-1191.
151. Miyamoto K, Waki Y, Horita T, Kasugai S, and Ohya K (1997) Reduction of bone loss by denbufylline, an inhibitor of phosphodiesterase 4. Biochem Pharmacol 54:613-617.
152. Mongillo M, Tocchetti CG, Terrin A, Lissandron V, Cheung YF, Dostmann WR, Pozzan T, Kass DA, Paolocci N, Houslay MD, et al. (2006) Compartmentalized phosphodiesterase-2 activity blunts β-adrenergic cardiac inotropy via an NO/cGMP-dependent pathway. Circ Res 98:226-234.
153. Morin F, Lugnier C, Kameni J, and Voisin P (2001) Expression and role of phosphodiesterase 6 in the chicken pineal gland. J Neurochem 78:88-99.
154. Muradov KG, Granovsky AE, and Artemyev NO (2003) Mutation in rod PDE6 linked to congenital stationary night blindness impairs the enzyme inhibition by its gamma-subunit. Biochemistry 42:3305-3310.
155. Murray F, MacLean MR, and Pyne NJ (2002) Increased expression of the cGMP-inhibited cAMP-specific (PDE3) and cGMP binding cGMP-specific (PDE5) phosphodiesterases in models of pulmonary hypertension. Br J Pharmacol 137:1187-1194.
156. Nakata A, Ogawa K, Sasaki T, Koyama N, Wada K, Kotera J, Kikkawa H, Omori K, and Kaminuma O (2002) Potential role of phosphodiesterase 7 in human T cell function: comparative effects of two phosphodiesterase inhibitors. Clin Exp Immunol 128:460-466.
157. Nikolaev VO, Gambaryan S, Engelhardt S, Walter U, and Lohse MJ (2005) Real-time monitoring of the PDE2 activity of live cells: hormone-stimulated cAMP hydrolysis is faster than hormone-stimulated cAMP synthesis. J Biol Chem 280:1716-1719.
158. Norton AW, Hosier S, Terew JM, Li N, Dhingra A, Vardi N, Baehr W, and
159. O'Connor V, Genin A, Davis S, Karishma KK, Doyere V, De Zeeuw CI, Sanger G, Hunt SP, Richter-Levin G, Mallet J, et al. (2004) Differential amplification of intron-containing transcripts reveals long term potentiation-associated upregulation of specific Pde10A phosphodiesterase splice variants. J Biol Chem 279:15841-15849.
160. Oh TY, Kang KK, Ahn BO, Yoo M, and Kim WB (2000) Erectogenic effect of the selective phosphodiesterase type 5 inhibitor, DA-8159. Arch Pharm Res (NY) 23:471-476.
161. Onuma H, Osawa H, Yamada K, Ogura T, Tanabe F, Granner DK, and Makino H (2002) Identification of the insulin-regulated interaction of phosphodiesterase 3B with 14-3-3 beta protein. Diabetes 51:3362-3367.
162. Ovchinnikov YA, Lipkin VM, Kumarev VP, Gubanov VV, Khramtsov NV, Akhmedov NB, Zagranichny VE, and Muradov KG (1986) Cyclic GMP phosphodiesterase from cattle retina: amino acid sequence of the γ-subunit and nucleotide sequence of the corresponding cDNA. FEBS Lett 204:288-292.
163. Padma-Nathan H, McMurray JG, Pullman WE, Whitaker JS, Saoud JB, Ferguson KM, and Rosen RC (2001) On-demand IC351 (Cialis) enhances erectile function in patients with erectile dysfunction. Int J Impot Res 13:2-9.
164. Palmer D and Maurice DH (2000) Dual expression and differential regulation of phosphodiesterase 3A and phosphodiesterase 3B in human vascular smooth muscle: implications for phosphodiesterase 3 inhibition in human cardiovascular tissues. Mol Pharmacol 58:247-252.
165. Patrucco E, Notte A, Barberis L, Selvetella G, Maffei A, Brancaccio M, Marengo S, Russo G, Azzolino O, Rybalkin SD, et al. (2004) PI3Kγ modulates the cardiac response to chronic pressure overload by distinct kinase-dependent and -independent effects. Cell 118:375-387.
166. 2-adrenergic receptors by β-arrestins. Science (Wash DC) 298:834-836.
167. Podzuweit T, Nennstiel P, and Muller A (1995) Isozyme selective inhibition of cGMP-stimulated cyclic nucleotide phosphodiesterases by erythro-9-(2-hydroxy-3-nonyl) adenine. Cell Signal 7:733-738.
168. Prickaerts J, Sik A, van Staveren WC, Koopmans G, Steinbusch HW, van der Staay FJ, de Vente J, and Blokland A (2004) Phosphodiesterase type 5 inhibition improves early memory consolidation of object information. Neurochem Int 45:915-928.
169. Rahn Landstrom T, Mei J, Karlsson M, Manganiello V, and Degerman E (2000) Down-regulation of cyclic-nucleotide phosphodiesterase 3B in 3T3-L1 adipocytes induced by tumour necrosis factor α and cAMP. Biochem J 346 (Pt 2):337-343.
170. Reed TM, Repaske DR, Snyder GL, Greengard P, and Vorhees CV (2002) Phosphodiesterase 1B knock-out mice exhibit exaggerated locomotor hyperactivity and DARPP-32 phosphorylation in response to dopamine agonists and display impaired spatial learning. J Neurosci 22:5188-5197.
171. Rena G, Begg F, Ross A, MacKenzie C, McPhee I, Campbell L, Huston E, Sullivan M, and Houslay MD (2001) Molecular cloning, genomic positioning, promoter identification, and characterization of the novel cyclic amp-specific phosphodiesterase PDE4A10. Mol Pharmacol 59:996-1011.
172. Reneland RH, Mah S, Kammerer S, Hoyal CR, Marnellos G, Wilson SG, Sambrook PN, Spector TD, Nelson MR, and Braun A (2005) Association between a variation in the phosphodiesterase 4D gene and bone mineral density. BMC Med Genet 6:9.
173. Rentero C, Monfort A, and Puigdomenech P (2003) Identification and distribution of different mRNA variants produced by differential splicing in the human phosphodiesterase 9A gene. Biochem Biophys Res Commun 301:686-692.
174. Richter W, Jin SL, and Conti M (2005) Splice variants of the cyclic nucleotide phosphodiesterase PDE4D are differentially expressed and regulated in rat tissue. Biochem J 388 (Pt 3): 803-811.
175. Ridge KD, Abdulaev NG, Sousa M, and Palczewski K (2003) Phototransduction: crystal clear. Trends Biochem Sci 28:479-487.
176. Rodefer JS, Murphy ER, and Baxter MG (2005) PDE10A inhibition reverses subchronic PCP-induced deficits in attentional set-shifting in rats. Eur J Neurosci 21:1070-1076.
177. Rondinone CM, Carvalho E, Rahn T, Manganiello VC, Degerman E, and Smith UP (2000) Phosphorylation of PDE3B by phosphatidylinositol 3-kinase associated with the insulin receptor. J Biol Chem 275:10093-10098.
178. Rosen RC and Kostis JB (2003) Overview of phosphodiesterase 5 inhibition in erectile dysfunction. Am J Cardiol 92: 9M-18M.
179. Rosman GJ, Martins TJ, Sonnenburg WK, Beavo JA, Ferguson K, and Loughney K (1997) Isolation and characterization of human cDNAs encoding a cGMP-stimulated 3′,5′-cyclic nucleotide phosphodiesterase. Gene 191:89-95.
180. Ruppert D and Weithmann KU (1982) HL 725, an extremely potent inhibitor of platelet phosphodiesterase and induced platelet aggregation in vitro. Life Sci 31:2037-2043.
181. Rybalkin SD, Rybalkina IG, Shimizu-Albergine M, Tang XB, and Beavo JA (2003a) PDE5 is converted to an activated state upon cGMP binding to the GAF A domain. EMBO (Eur Mol Biol Organ) J 22:469-478.
182. Rybalkin SD, Yan C, Bornfeldt KE, and Beavo JA (2003b) Cyclic GMP phosphodiesterases and regulation of smooth muscle function. Circ Res 93:280-291.
183. Sadhu K, Hensley K, Florio VA, and Wolda SL (1999) Differential expression of the cyclic GMP-stimulated phosphodiesterase PDE2A in human venous and capillary endothelial cells. J Histochem Cytochem 47:895-905.
184. Salanova M, Jin SLC, and Conti M (1998) Heterologous expression and purification of recombinant rolipram-sensitive cyclic AMP-specific phosphodiesterases. Methods Companion Methods Enzymol 14:55-64.
185. Saleheen D, Bukhari S, Haider SR, Nazir A, Khanum S, Shafqat S, Anis MK, and Frossard P (2005) Association of phosphodiesterase 4D gene with ischemic stroke in a Pakistani population. Stroke 36:2275-2277.
186. Sasaki T, Kotera J, and Omori K (2002) Novel alternative splice variants of rat phosphodiesterase 7B showing unique tissue-specific expression and phosphorylation. Biochem J 2:211-220.
187. Sasaki T, Kotera J, and Omori K (2004) Transcriptional activation of phosphodiesterase 7B1 by dopamine D1 receptor stimulation through the cyclic AMP/cyclic AMP-dependent protein kinase/cyclic AMP-response element binding protein pathway in primary striatal neurons. J Neurochem 89:474-483.
188. Sasaki T Kotera J, Yuasa K, and Omori K (2000) Identification of human PDE7B, a cAMP-specific phosphodiesterase. Biochem Biophys Res Commun 271:575-583.
189. Scapin G, Patel SB, Chung C, Varnerin JP, Edmondson SD, Mastracchio A, Parmee ER, Singh SB, Becker JW, Van der Ploeg LH, et al. (2004) Crystal structure of human phosphodiesterase 3B: atomic basis for substrate and inhibitor specificity. Biochemistry 43:6091-6100.
190. Schmidt DT, Watson N, Dent G, Ruhlmann E, Branscheid D, Magnussen H, and Rabe KF (2000) The effect of selective and non-selective phosphodiesterase inhibitors on allergen- and leukotriene C-4-induced contractions in passively sensitized human airways. Br J Pharmacol 131:1607-1618.
191. Schwabe U, Miyake M, Ohga Y, and Daly JW (1976) 4-(3-Cyclopentyloxy-4- methoxyphenyl)-2-pyrrolidone (ZK 62711): a potent inhibitor of adenosine cyclic 3′,5′-monophosphate phosphodiesterases in homogenates and tissue slices from rat brain. Mol Pharmacol 12:900-910.
192. Seeger TF, Bartlett B, Coskran TM, Culp JS, James LC, Krull DL, Lanfear J, Ryan AM, Schmidt CJ, Strick CA, et al. (2003) Immunohistochemical localization of PDE10A in the rat brain. Brain Res 985:113-126.
193. Sette C and Conti M (1996) Phosphorylation and activation of a cAMP-specific phosphodiesterase by the cAMP-dependent protein kinase - involvement of serine 54 in the enzyme activation. J Biol Chem 271:16526-16534.
194. Sette C, Iona S, and Conti M (1994) The short-term activation of a rolipram-sensitive, cAMP-specific phosphodiesterase by thyroid-stimulating hormone in thyroid FRTL-5 cells is mediated by a cAMP-dependent phosphorylation. J Biol Chem 269:9245-9252.
195. Setter SM, Iltz JL, Fincham JE, Campbell RK, and Baker DE (2005) Phosphodiesterase 5 inhibitors for erectile dysfunction. Ann Pharmacother 39:1286-1295.
196. Seybold J, Thomas D, Witzenrath M, Boral S, Hocke AC, Burger A, Hatzelmann A, Tenor H, Schudt C, Krull M, et al. (2005) Tumor necrosis factor-α-dependent expression of phosphodiesterase 2: role in endothelial hyperpermeability. Blood 105:3569-3576.
197. Shakur Y, Holst LS, Landstrom TR, Movsesian M, Degerman E, and Manganiello V (2001) Regulation and function of the cyclic nucleotide phosphodiesterase (PDE3) gene family. Prog Nucleic Acid Res Mol Biol 66:241-277.
198. Sharma RK, Adachi AM, Adachi K, and Wang JH (1984) Demonstration of bovine brain calmodulin-dependent cyclic nucleotide phosphodiesterase isozymes by monoclonal antibodies. J Biol Chem 259:9248-9254.
199. Sharma RK and Wang JH (1985) Differential regulation of bovine brain calmodul-independent cyclic nucleotide phosphodiesterase isoenzymes by cyclic AMP-dependent protein kinase and calmodulin-dependent phosphatase. Proc Natl Acad Sci USA 82:2603-2607.
200. 2+-dependent phosphorylation and dephosphorylation of 63-kDa subunit-containing bovine brain calmodulin-stimulated cyclic nucleotide phosphodiesterase isozyme. J Biol Chem 261:1322-1328.
201. Sheppard H and Tsien WH (1975) Alterations in the hydrolytic activity, inhibitor sensitivity and molecular size of the rat erythrocyte cyclic AMP phosphodiesterase by calcium and hypertonic sodium chloride. J Cyclic Nucleotide Res 1:237-242.
202. Shimizu-Albergine M, Rybalkin SD, Rybalkina IG, Feil R, Wolfsgruber W, Hofmann F, and Beavo J A (2003) Individual cerebellar Purkinje cells express different cGMP phosphodiesterases (PDEs): in vivo phosphorylation of cGMP-specific PDE (PDE5) as an indicator of cGMP-dependent protein kinase (PKG) activation. J Neurosci 23:6452-6459.
203. Smith SJ, Brookes-Fazakerley S, Donnelly LE, Barnes PJ, Barnette MS, and Giembycz MA (2003) Ubiquitous expression of phosphodiesterase 7A in human proinflammatory and immune cells. Am J Physiol 284:L279-L289.
204. + T-lymphocytes. Mol Pharmacol 66:1679-1689.
205. Snyder PB, Esselstyn JM, Loughney K, Wolda SL, and Florio VA (2005) The role of cyclic nucleotide phosphodiesterases in the regulation of adipocyte lipolysis. J Lipid Res 46:494-503.
206. 2+/ calmodulin-stimulated phosphodiesterase (PDE1A). Cell Signal 11:535-544.
207. Soderling SH, Bayuga SJ, and Beavo JA (1998a) Cloning and characterization of a cAMP-specific cyclic nucleotide phosphodiesterase. Proc Natl Acad Sci USA 95:8991-8996.
208. Soderling SH, Bayuga SJ, and Beavo JA (1998b) Identification and characterization of a novel family of cyclic nucleotide phosphodiesterases. J Biol Chem 273:15553-15558.
209. Soderling SH, Bayuga SJ, and Beavo JA (1999) Isolation and characterization of a dual-substrate phosphodiesterase gene family: PDE10A. Proc Natl Acad Sci USA 96:7071-7076.
210. Sonnenburg WK, Seger D, Kwak KS, Huang J, Charbonneau H, and Beavo JA (1995) Identification of inhibitory and calmodulin-binding domains of the PDE1A1 and PDE1A2 calmodulin-stimulated cyclic nucleotide phosphodiesterases. J Biol Chem 270:989-1000.
211. Sonnenburg WK, Wayman GA, Storm DR, and Beavo JA (1998) Cyclic nucleotide regulation by calmodulin, in Calmodulin and Signal Transduction (Van Eldik LJ and Watterson DM eds) pp 237-287, Academic Press, San Diego.
212. Sopory S, Balaji S, Srinivasan N, and Visweswariah SS (2003) Modeling and mutational analysis of the GAF domain of the cGMP-binding, cGMP-specific phosphodiesterase, PDE5. FEBS Lett 539:161-166.
213. Souness JE and Rao S (1997) Proposal for pharmacologically distinct conformers of PDE4 cyclic AMP phosphodiesterases. Cell Signal 9: 227-236.
214. Stacey P, Rulten S, Dapling A, and Phillips SC (1998) Molecular cloning and expression of human cGMP-binding cGMP-specific phosphodiesterase (PDE5). Biochem Biophys Res Commun 247:249-254.
215. Steiner MK, Preston IR, Klinger JR, and Hill NS (2005) Pulmonary hypertension: inhaled nitric oxide, sildenafil and natriuretic peptides. Curr Opin Pharmacol 5:245-250.
216. Sudo T, Tachibana K, Toga K, Tochizawa S, Inoue Y, Kimura Y, and Hidaka H (2000) Potent effects of novel anti-platelet aggregatory cilostamide analogues on recombinant cyclic nucleotide phosphodiesterase isozyme activity. Biochem Pharmacol 59:347-356.
217. Sung BJ, Hwang KY, Jeon YH, Lee JI, Heo YS, Kim JH, Moon J, Yoon JM, Hyun YL, Kim E, et al. (2003) Structure of the catalytic domain of human phosphodiesterase 5 with bound drug molecules. Nature (Lond) 425:98-102.
218. Suvarna NU and O'Donnell JM (2002) Hydrolysis of N-methyl-D-aspartate receptor-stimulated cAMP and cGMP by PDE4 and PDE2 phosphodiesterases in primary neuronal cultures of rat cerebral cortex and hippocampus. J Pharmacol Exp Ther 302:249-256.
219. Takimoto E, Champion HC, Li M, Belardi D, Ren S, Rodriguez ER, Bedja D, Gabrielson KL, Wang Y, and Kass DA (2005) Chronic inhibition of cyclic GMP phosphodiesterase 5A prevents and reverses cardiac hypertrophy. Nat Med 11:214-222.
220. Tanaka T, Ishikawa T, Hagiwara M, Onoda K, Itoh H, and Hidaka H (1988) Effects of cilostazol, a selective cAMP phosphodiesterase inhibitor on the contraction of vascular smooth muscle. Pharmacology 36:313-320.
221. Tasken KA, Collas P, Kemmner WA, Witczak O, Conti M, and Tasken K (2001) Phosphodiesterase 4D and protein kinase a type II constitute a signaling unit in the centrosomal area. J Biol Chem 276:21999-22002.
222. Tcheudji JF, Lebeau L, Virmaux N, Maftei CG, Cote RH, Lugnier C, and Schultz P (2001) Molecular organization of bovine rod cGMP-phosphodiesterase 6. J Mol Biol 310:781-791.
223. Tenor H and Schudt C (1996) Analysis of PDE isoenzyme profiles in cells and tissues by pharmacological methods, in Phosphodiesterase Inhibitors (Schudt C, Dent G, and Rabe K eds) pp 21-40, Academic Press, London.
224. Terry R, Cheung YF, Praestegaard M, Baillie GS, Huston E, Gall I, Adams DR, and Houslay MD (2003) Occupancy of the catalytic site of the PDE4A4 cyclic AMP phosphodiesterase by rolipram triggers the dynamic redistribution of this specific isoform in living cells through a cyclic AMP independent process. Cell Signal 15:955-971.
225. Thomason PA, Traynor D, Stock JB, and Kay RR (1999) The RdeA-RegA system, a eukaryotic phospho-relay controlling cAMP breakdown. J Biol Chem 274:27379-27384.
226. Thompson WJ, Terasaki WL, Epstein PM, and Strada SJ (1979) Assay of cyclic nucleotide phosphodiesterase and resolution of multiple molecular forms of the enzyme. Adv Cyclic Nucleotide Res 10:69-92.
227. Torras-Llort M and Azorin F (2003) Functional characterization of the human phosphodiesterase 7A1 promoter. Biochem J 373 (Pt 3):835-843.
228. Van Staveren WC, Glick J, Markerink-Van Ittersum M, Shimizu M, Beavo JA, Steinbusch HW, and De Vente J (2002) Cloning and localization of the cGMP-specific phosphodiesterase type 9 in the rat brain. J Neurocytol 31:729-741.
229. 2+ channel current in human atrial myocytes. J Physiol 533 (Pt 2): 329-340.
230. Vasta V, Sonnenburg WK, Yan C, Soderling SH, Shimizu-Albergine M, and Beavo JA (2005) Identification of a new variant of PDE1A calmodulin-stimulated cyclic nucleotide phosphodiesterase expressed in mouse sperm. Biol Reprod 73:598-609.
231. Verde I, Pahlke G, Salanova M, Zhang G, Wang S, Coletti D, Onuffer J, Jin SLC, and Conti M (2001) Myomegalin is a novel protein of the Golgi/centrosome that interacts with a cyclic nucleotide phosphodiesterase. J Biol Chem 276: 11189-11198.
232. Wachtel H (1982) Characteristic behavioural alterations in rats induced by rolipram and other selective adenosine cyclic 3′,5′-monophosphate phosphodiesterase inhibitors. Psychopharmacology 77:309-316.
233. Wallace DA, Johnston LA, Huston E, MacMaster D, Houslay TM, Cheung YF, Campbell L, Millen JE, Smith RA, Gall I, et al. (2005) Identification and characterization of PDE4A11, a novel, widely expressed long isoform encoded by the human PDE4A cAMP phosphodiesterase gene. Mol Pharmacol 67:1920-1934.
234. 2+/cGMP-signalling pathway in development. Biochem Soc Trans 32 (Pt 5):792-796.
235. Wang H, Liu Y, Chen Y, Robinson H, and Ke H (2005) Multiple elements jointly determine inhibitor selectivity of cyclic nucleotide phosphodiesterases 4 and 7. J Biol Chem 280:30949-30955.
236. Wang P, Myers JG, Wu P, Cheewatrakoolpong B, Egan RW, and Billah MM (1997) Expression, purification, and characterization of human cAMP-specific phosphodiesterase (PDE4) subtypes A, B, C, and D. Biochem Biophys Res Commun 234:320-324.
237. Wang P, Wu P, Egan RW, and Billah MM (2001) Human phosphodiesterase 8A splice variants: cloning, gene organization, and tissue distribution. Gene 280:183-194.
238. Wang P, Wu P, Egan RW, and Billah MM (2003) Identification and characterization of a new human type 9 cGMP-specific phosphodiesterase splice variant (PDE9A5). Differential tissue distribution and subcellular localization of PDE9A variants. Gene 314:15-27.
239. Watkins RW, Davis HR Jr, Fawzi A, Ahn HS, Cook J, Cleven R, Hoods L, McGregor D, McLeod R, et al. (1995) Antihypertensive, hemodynamic and vascular protective effects of SCH 51866, an inhibitor of cGMP hydrolysis. FASEB J. 9:A342.
240. Wayman C, Phillips S, Lunny C, Webb T, Fawcett L, Baxendale R, and Burgess G (2005) Phosphodiesterase 11 (PDE11) regulation of spermatozoa physiology. Int J Impot Res 17:216-223.
241. Wechsler J, Choi YH, Krall J, Ahmad F, Manganiello VC, and Movsesian MA (2002) Isoforms of cyclic nucleotide phosphodiesterase PDE3A in cardiac myocytes. J Biol Chem 277:38072-38078.
242. Weeks JL, Zoraghi R, Beasley A, Sekhar KR, Francis SH, and Corbin JD (2005) High biochemical selectivity of tadalafil, sildenafil and vardenafil for human phosphodiesterase 5A1 (PDE5) over PDE11A4 suggests the absence of PDE11A4 cross-reaction in patients. Int J Impot Res 17:5-9.
243. Witwicka H, Kobialka M, and Gorczyca WA (2002) Hydrolysis of cyclic GMP in rat peritoneal macrophages. Acta Biochim Pol 49:891-897.
244. Wollert KC, Fiedler B, Gambaryan S, Smolenski A, Heineke J, Butt E, Trautwein C, Lohmann SM, and Drexler H (2002) Gene transfer of cGMP-dependent protein kinase I enhances the antihypertrophic effects of nitric oxide in cardiomyocytes. Hypertension 39:87-92.
245. Wong W and Scott JD (2004) AKAP signalling complexes: focal points in space and time. Nat Rev Mol Cell Biol 5:959-970.
246. Wu AY, Tang XB, Martinez SE, Ikeda K, and Beavo JA (2004) Molecular determinants for cyclic nucleotide binding to the regulatory domains of phosphodiesterase 2A. J Biol Chem 279:37928-37938.
247. Wunder F, Tersteegen A, Rebmann A, Erb C, Fahrig T, and Hendrix M (2005) Characterization of the first potent and selective PDE9 inhibitor using a cGMP reporter cell line. Mol Pharmacol 68:1775-1781.
248. Wykes V, Bellamy TC, and Garthwaite J (2002) Kinetics of nitric oxide-cyclic GMP signalling in CNS cells and its possible regulation by cyclic GMP. J Neurochem 83:37-47.
249. 2 adrenoceptor subtype-specific signaling in cardiac myocytes. Proc Natl Acad Sci USA 102:909-914.
250. Xu RX, Hassell AM, Vanderwall D, Lambert MH, Holmes WD, Luther MA, Rocque WJ, Milburn MV, Zhao Y, Ke H, et al. (2000) Atomic structure of PDE4: insights into phosphodiesterase mechanism and specificity. Science (Wash DC) 288:1822-1825.
251. Xu RX, Rocque WJ, Lambert MH, Vanderwall DE, Luther MA, and Nolte RT (2004) Crystal structures of the catalytic domain of phosphodiesterase 4B complexed with AMP, 8-Br-AMP, and rolipram. J Mol Biol 337:355-365.
252. Yamamoto T, Manganiello VC, and Vaughan M (1983) Purification and characterization of cyclic GMP-stimulated cyclic nucleotide phosphodiesterase from calf liver: effects of divalent cations on activity. J Biol Chem 258:12526-12533.
253. Yan C, Zhao AZ, Bentley JK, and Beavo JA (1996) The calmodulin-dependent phosphodiesterase gene PDE1C encodes several functionally different splice variants in a tissue-specific manner. J Biol Chem 271:25699-25706.
254. Yan C, Zhao AZ, Bentley JK, Loughney K, Ferguson K, and Beavo JA (1995) Molecular cloning and characterization of a calmodulin-dependent phosphodiesterase enriched in olfactory sensory neurons. Proc Natl Acad Sci U.S.A. 92:9677-9681.
255. Yan C, Zhao AZ, Sonnenburg WK, and Beavo JA (2001) Stage and cell-specific expression of calmodulin-dependent phosphodiesterases in mouse testis. Biol Reprod 64:1746-1754.
256. Yanaka N, Kotera J, Ohtsuka A, Akatsuka H, Imai Y, Michibata H, Fujishige K, Kawai E, Takebayashi S, Okumura K, et al. (1998) Expression, structure and) Thchromosomal localization of the human cGMP-binding cGMP-specific phosphodiesterase PDE5A gene. Eur J Biochem 255:391-399.
257. Yang G, McIntyre KW, Townsend RM, Shen HH, Pitts WJ, Dodd JH, Nadler SG, McKinnon M, and Watson AJ (2003) Phosphodiesterase 7A-deficient mice have functional T cells. J Immunol 171:6414-6420.
258. Yarwood SJ, Steele MR, Scotland G, Houslay MD, and Bolger GB (1999) RACK1 signaling scaffold protein selectively interacts with the cAMP-specific phosphodiesterase PDE4D5 isoform. J Biol Chem 274:14909-14917; erratum (2001) 276:6879.
259. Yuasa K, Kanoh Y, Okumura K, and Omori K (2001a) Genomic organization of the human phosphodiesterase PDE11A gene: evolutionary relatedness with other PDEs containing GAF domains. Eur J Biochem 268:168-178.
260. Yuasa K, Kotera J, Fujishige K, Michibata H, Sasaki T, and Omori K (2000) Isolation and characterization of two novel phosphodiesterase PDE11A variants showing unique structure and tissue-specific expression. J Biol Chem 275:31469-31479.
261. Yuasa K, Ohgaru T, Asahina M, and Omori K (2001b) Identification of rat cyclic nucleotide phosphodiesterase 11A (PDE11A): comparison of rat and human PDE11A splicing variants. Eur J Biochem 268:4440-4448.
262. Zahabi A, Picard S, Fortin N, Reudelhuber TL, and Deschepper CF (2003) Expression of constitutively active guanylate cyclase in cardiomyocytes inhibits the hypertrophic effects of isoproterenol and aortic constriction on mouse hearts. J Biol Chem 278:47694-47699.
263. Zhang HT, Huang Y, Suvarna NU, Deng C, Crissman AM, Hopper AT, De Vivo M, Rose GM, and O'Donnell JM (2005) Effects of the novel PDE4 inhibitors MEM1018 and MEM1091 on memory in the radial-arm maze and inhibitory avoidance tests in rats. Psychopharmacology 179:613-619.
264. Zhang HT, Zhao Y, Huang Y, Dorairaj NR, Chandler LJ, and O'Donnell JM (2004a) Inhibition of the phosphodiesterase 4 (PDE4) enzyme reverses memory deficits produced by infusion of the MEK inhibitor U0126 into the CA1 subregion of the rat hippocampus. Neuropsychopharmacology 29:1432-1439.
265. Zhang KY, Card GL, Suzuki Y, Artis DR, Fong D, Gillette S, Hsieh D, Neiman J, West BL, Zhang C, et al. (2004b) A glutamine switch mechanism for nucleotide selectivity by phosphodiesterases. Mol Cell 15:279-286.
266. Zhao AZ, Bornfeldt KE, and Beavo JA (1998) Leptin inhibits insulin secretion by activation of phosphodiesterase 3B. J Clin Investig 102:869-873.
267. Zhao AZ, Huan JN, Gupta S, Pal R, and Sahu A (2002) A phosphatidylinositol 3-kinase phosphodiesterase 3B-cyclic AMP pathway in hypothalamic action of leptin on feeding. Nat Neurosci 5:727-728.
268. Zhao AZ, Zhao H, Teague J, Fujimoto W, and Beavo JA (1997) Attenuation of insulin secretion by insulin-like growth factor 1 is mediated through activation of phosphodiesterase 3B. Proc Natl Acad Sci USA 94:3223-3228.
269. Zoraghi R, Bessay EP, Corbin JD, and Francis SH (2005) Structural and functional features in human PDE5A1 regulatory domain that provide for allosteric cGMP binding, dimerization, and regulation. J Biol Chem 280:12051-12063.
270. Zoraghi R, Corbin JD, and Francis SH (2006) Phosphodiesterase-5 Gln-817 is critical for cGMP, vardenafil, or sildenafil affinity: its orientation impacts cGMP but not cAMP affinity. J Biol Chem 281:5553-5558.